← FDA DRUG APPROVALS

FDA ANDA · ANDA076689

MIRTAZAPINE

Sponsor: ACTAVIS ELIZABETH

APPLICATION
ANDA076689
TYPE
ANDA
ORIGINAL APPROVAL
2005-08-31
LATEST ACTION
2008-07-23
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Discontinued

Products

MIRTAZAPINEDiscontinued
MIRTAZAPINE 30MG · TABLET, ORALLY DISINTEGRATING · ORAL
MIRTAZAPINEDiscontinued
MIRTAZAPINE 45MG · TABLET, ORALLY DISINTEGRATING · ORAL
MIRTAZAPINEDiscontinued
MIRTAZAPINE 15MG · TABLET, ORALLY DISINTEGRATING · ORAL

Approval history

2008-07-23Labeling · Supplement 4AP
2005-08-31Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →